ArticleEpilepsia2019
Medication treatment for attention-deficit/hyperactivity disorder and the risk of acute seizures in individuals with epilepsy.
Article in Epilepsia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Epilepsy and attention-deficit/hyperactivity disorder in children and adolescents: An overview of etiology, prevalence, and treatment.Frontiers in human neuroscience · 2023Pooled it
- Psychiatric Comorbidities in Pediatric Epilepsy.Current psychiatry reports · 2020Pooled it
- Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases.Biological psychiatry · 2019Pooled it
- Long term safety of ADHD medication in patients with schizophrenia spectrum disorders.Molecular psychiatry · 2025Article
- ADHD in Adults with Epilepsy: A Guide for Neurologists.Epilepsy & behavior reports · 2025Article
- Children with ADHD and EEG abnormalities at baseline assessment, risk of epileptic seizures and maintenance on methylphenidate three years later.Annals of general psychiatry · 2024Article
- Attention-Deficit/Hyperactivity Disorder Medications and Work Disability and Mental Health Outcomes.JAMA network open · 2024Article
- Do psychotropic drugs cause seizures?Epilepsy & behavior reports · 2024Article
- Should neurologists treat common psychiatric comorbidities in patients with epilepsy?Epilepsy & behavior reports · 2024Article
- Screening for ADHD in Adult Patients With Epilepsy: Prevalence of Symptoms and Challenges to Diagnosis.Journal of attention disorders · 2024Article
- The impact of anti-seizure medications on psychiatric disorders among children with epilepsy: Both a challenge and an opportunity?Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent · 2023Review
- Case Report: Guanfacine and methylphenidate improved chronic lower back pain in autosomal dominant polycystic kidney disease with comorbid attention deficit hyperactivity disorder and autism spectrum disorder.Frontiers in pediatrics · 2023Article
- Pharmacologic Therapies to Promote Recovery of Consciousness.Seminars in neurology · 2022Article
- Easing the Journey-an Updated Review of Palliative Care for the Patient with High-Grade Glioma.Current oncology reports · 2022Review
- Methylphenidate and TBI in ADHD and co-occurring epilepsy and mental disorders: a self-controlled case series study.European child & adolescent psychiatry · 2022Article
- Do Psychotropic Drugs Cause Epileptic Seizures? A Review of the Available Evidence.Current topics in behavioral neurosciences · 2022Review
- Psychiatric Comorbidities in People With Epilepsy.Neurology. Clinical practice · 2021Review
- Methylphenidate for attention problems in epilepsy patients: Safety and efficacy.Epilepsy & behavior : E&B · 2021Review
- The effect of Omaha System-based continuous nursing care on the psychological status, self-esteem, and quality of life in epileptic children.American journal of translational research · 2021Article
- Use of medication for attention-deficit/hyperactivity disorder and risk of unintentional injuries in children and adolescents with co-occurring neurodevelopmental disorders.Journal of child psychology and psychiatry, and allied disciplines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveAttention-deficit/hyperactivity disorder (ADHD) affects 10%-30% of individuals with epilepsy, yet concerns remain regarding the safety of ADHD medication in this group. The objective of this study was to examine the risk of acute seizures associated with ADHD medication in individuals with epilepsy.
methodsA total of 21 557 individuals with a seizure history born between 1987 and 2003 were identified from Swedish population registers. Within this study population, we also identified 6773 youth (<19 years of age) who meet criteria for epilepsy, and 1605 youth with continuous antiepileptic drug (AED) treatment. ADHD medication initiation and repeated medication periods were identified from the Swedish Prescribed Drug Register between January 1, 2006 and December 31, 2013. Acute seizures were identified via unplanned visits to hospital or specialist care with a primary seizure discharge diagnosis in the Swedish National Patient Register during the same period. Conditional Poisson regression was used to compare the seizure rate during the 24 weeks before and after initiation of ADHD medication with the rate during the same 48 weeks in the previous year. Cox regression was used to compare the seizure rate during ADHD medication periods with the rate during nonmedication periods. Comparisons were made within-individual to adjust for unmeasured, time?constant confounding.
resultsAmong 995 individuals who initiated ADHD medication during follow-up, within-individual analyses showed no statistically significant difference in the rate of seizures during the 24 weeks before and after medication initiation, compared to the same period in the previous year. In the full study population 11 754 seizure events occurred during 136 846 person-years and 1855 individuals had at least one ADHD medication period. ADHD medication periods were associated with a reduced rate of acute seizures (hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.57-0.94), compared to nonmedication periods within the same individual. Similar associations were found in youth with epilepsy and continuous AED treatment, when adjusting for AEDs, and across sex, age, and comorbid neurodevelopmental disorders. SIGNIFICANCE: We found no evidence for an overall increased rate of acute seizures associated with ADHD medication treatment among individuals with epilepsy. These results suggest that epilepsy should not automatically preclude patients from receiving ADHD medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.